CRBU

Caribou Biosciences, Inc.

BS score 44.8LOWPHASE1 · mkt cap $189.4M · rev ttm $11.2M

drug hypothesis

CB-010 modulates CD19 to treat Relapsed/Refractory B Cell Non-Hodgkin Lymphoma.

moa:CRISPR-edited allogeneic (off-the-shelf) CAR-T cell therapy targeting CD19-positive B cells for destruction via T-cell mediated cytotoxicity

score breakdown

trial design70

base rate disconnect22

language red flags40

composite44.8

valuation analysis

market cap$189.4M

revenue ttm$11.2M

phasePHASE1

historical base rate5%

disconnect ratio0.8x

lead trialNCT04637763

meta

cik0001619856

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 1 non-randomized, single-arm trial (ANTLER) enrolling 72 patients with relapsed/refractory B cell non-Hodgkin lymphoma; lymphodepletion with cyclophosphamide and fludarabine prior to CB-010 infusion; Part A focuses on dose-limiting toxicities

primary endpoint:Number of patients with dose-limiting toxicities (Part A) within 28 days following CB-010 infusion

claimed differentiation

Allogeneic (off-the-shelf) format potentially enables faster availability than autologous CAR-T therapies; CRISPR gene editing platform (specific edits not specified in available data)

language red flags

SEC filing text not provided - cannot assess company's claimed differentiation or risk language
Trial data alone shows standard Phase 1 design with safety as primary endpoint - no explicit promotional language to assess

company-stated risks

Dose-limiting toxicities (explicitly monitored as primary endpoint)
Risks typical of allogeneic CAR-T including graft-versus-host disease, host-versus-graft rejection, and immune rejection

upcoming catalysts

2025-08Primary trial completion